← Back to Clinical Trials
Recruiting NCT06943781

NCT06943781 Prospective Gastric Cancer Screening Using Helicobacter Pylori High-Risk Single Nucleotide Polymorphism Detection

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06943781
Status Recruiting
Phase
Sponsor Fudan University
Condition Gastric Adenocarcinoma
Study Type OBSERVATIONAL
Enrollment 15,000 participants
Start Date 2025-07-01
Primary Completion 2027-07-01

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Fecal Helicobacter pylori gastric cancer susceptibility gene test

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 15,000 participants in total. It began in 2025-07-01 with a primary completion date of 2027-07-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a prospective study designed to compare the performance of fecal H. pylori gastric cancer susceptibility analysis and the gastric cancer risk questionnaire for the early detection of gastric cancer. The primary objective is to assess whether each method, individually or in combination, can facilitate earlier diagnosis of gastric cancer. All participants will undergo fecal H. pylori gastric cancer susceptibility testing and complete the gastric cancer risk questionnaire.

Eligibility Criteria

Inclusion Criteria: 1. Age ≥40 years, male or female. 2. No contraindications to endoscopy and able to cooperate with endoscopy. 3. Patients must be able to fully understand the informed consent form and be able to sign the informed consent form in person. Exclusion Criteria: 1. A history of diagnosed gastric cancer or other malignant tumors of the digestive tract. 2. Comorbid severe underlying conditions (e.g., severe cardiopulmonary insufficiency, liver or renal failure, etc.) that are likely to result in a short life expectancy or render long-term follow-up impractical. 3. Severe mental illness or incapacity to participate in the study due to lack of civil behavior. 4. Pregnant or breastfeeding women. 5. Other conditions that the investigator deems inappropriate for participation in the study.

Contact & Investigator

Central Contact

Dazhi Xu, PhD

✉ xudzh@fudan.edu.cn

📞 86-18121299796

Frequently Asked Questions

Who can join the NCT06943781 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, studying Gastric Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06943781 currently recruiting?

Yes, NCT06943781 is actively recruiting participants. Contact the research team at xudzh@fudan.edu.cn for enrollment information.

Where is the NCT06943781 trial being conducted?

This trial is being conducted at Tongling, China.

Who is sponsoring the NCT06943781 clinical trial?

NCT06943781 is sponsored by Fudan University. The trial plans to enroll 15,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology